CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 23 enrolled
Drug / intervention
Ruxolitinib +3 moredrug
Likely dose
Ruxolitinib 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02876302
NCT02876302Phase 2Active
CompareCT.gov

Phase II Study Of Combination Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

Dana-Farber Cancer Institute·interventional·Posted Aug 23, 2016·Updated Feb 4, 2026

In Brief

A Phase 2 clinical trial evaluating Ruxolitinib, Paclitaxel, and 2 other interventions for Inflammatory Breast Cancer (IBC). Active but no longer recruiting, targeting 23 participants across 4 sites.

Detailed Summary

This research study is studying Ruxolitinib as possible treatment for Inflammatory Breast Cancer (IBC). The Following drugs will be use in combination with Ruxolinitinib. * Paclitaxel (also called Taxol) * Doxorubicin also called Adriamycin * Cyclophosphamide, also called Cytoxan

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInflammatory Breast Cancer (IBC)
CountriesUnited States
CollaboratorsIncyte Corporation

Timeline

Phase 2ActiveOverdue
2017201820192020202120222023202420252026
First PostedAug 23, 2016
Enrollment StartJan 24, 2018
Primary CompletionDec 31, 2022
Study CompletionApr 1, 2026
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 9.9 years ago

Interventions

Ruxolitinibdrug

15 or 20 mg, twice daily by mouth. The run-in part of ruxolitinib lasts 7 days; The treatment of ruxolitinib part lasts 12 weeks.

Paclitaxeldrug

80 mg/m2, IV (in the vein) weekly for 12 weeks.

Doxorubicindrug

60 mg/m2, IV (in the vein) every 14 days for 4 doses.

Cyclophosphamidedrug

600 mg/m2, IV (in the vein) every 14 days for 4 doses.